CRON (Cronos Group) Risk Assessment

View and export this data going back to 2016. Start your Free Trial

What is Cronos Group Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Cronos Group is: High Risk: High uncertainty with risk-return tradeoff.

Competitive Comparison of Cronos Group's Risk Assessment

For the Drug Manufacturers - Specialty & Generic subindustry, Cronos Group's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cronos Group's Risk Assessment Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cronos Group's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Cronos Group's Risk Assessment falls into.

Cronos Group (NAS:CRON) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Cronos Group Risk Assessment Related Terms

Thank you for viewing the detailed overview of Cronos Group's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Cronos Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cronos Group Inc (NAS:CRON) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

7CI:Germany CRON:Canada

Address

111 Peter Street, Suite 300, Toronto, ON, CAN, M5V 2H1

Website

https://www.thecronosgroup.com

Cronos Group, headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the US, the company has an option to acquire 5.9% of US multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.

Executives

Kamran Khan	director	111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Elizabeth Seegar	director	111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Dominik Meier	director	111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Jason Marc Adler	director	111 PETER STREET, SUITE 300, TORONTO A6 M5V 2G9
Mcginness James Andrew Iii	officer: VP, Controller	C/O MARKETWISE, 1125 N. CHARLES STREET, BALTIMORE MD 21201
Maple Holdco (bermuda) Ltd.	10 percent owner	C/O ALTRIA GROUP, INC., 6601 WEST BROAD STREET, RICHMOND VA 23230
Maple Acquireco (canada) Ulc	10 percent owner	C/O ALTRIA GROUP, INC., 6601 WEST BROAD STREET, RICHMOND VA 23230
Altria Summit Llc	10 percent owner	C/O ALTRIA GROUP, INC., 6601 WEST BROAD STREET, RICHMOND VA 23230
Altria Group, Inc.	10 percent owner	6601 WEST BROAD STREET, RICHMOND VA 23230
James Holm	officer: Chief Financial Officer	111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Arye Weigensberg	officer: See Remarks	111 PETER STREET, SUITE 300, TORONTO A6 MV5 2H1
Doucet Terrence Gregory Joseph	officer: See Remarks	111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
John Griese	officer: See Remarks	111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Ran Gorelik	officer: General Manager (Israel)	111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Robert L Madore	officer: Chief Financial Officer	C/O RALPH LAUREN CORPORATION, 650 MADISON AVENUE, NEW YORK NY 10022